Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.57 |
| ▸ | SPR | P35270 | 2/20 | 0.52 |
| ▸ | APLNR | P35414 | 1/20 | 0.51 |
| ▸ | MGLL | Q99685 | 6/20 | 0.49 |
| ▸ | QDPR | P09417 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | CCR1 | P32246 | 1/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | CCR2 | P41597 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1808659 | 0.84 | KMT2A (0.49) | MEN1KMT2AMGLL | |
| SCHEMBL1811171 | 0.72 | EPHX2 (0.52) | SPRMGLLALDH1A1 | |
| SCHEMBL19658652 | 0.71 | QDPR (0.62) | QDPRALDH1A1CCR1 | |
| SCHEMBL13385518 | 0.70 | MGLL (0.71) | MEN1KMT2AMGLLLMNACCR1 | |
| SCHEMBL16963363 | 0.69 | CCR1 (0.57) | LMNACCR1TP53 | |
| SCHEMBL2098866 | 0.69 | HSD11B1 (0.58) | LMNACCR1TP53 | |
| SCHEMBL7893825 | 0.69 | GAA (0.80) | MEN1KMT2AALDH1A1L3MBTL1LMNA | |
| SCHEMBL17502641 | 0.69 | HPGD (0.69) | MEN1KMT2AALDH1A1LMNA | |
| SCHEMBL1808107 | 0.69 | HSD11B1 (0.47) | MEN1KMT2AMGLL | |
| SCHEMBL18058607 | 0.68 | TRPV6 (0.62) | MEN1KMT2AALDH1A1L3MBTL1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9051296-B2 | Aryl carboxamide derivatives as TTX-S blockers | RAQUALIA PHARMA INC. (JP) | 2015-06-09 | — | — | US | disclosed |
| US-20120232052-A1 | ARYL CARBOXAMIDE DERIVATIVES AS TTX-S BLOCKERS | RAQUALIA PHARMA INC. (JP) | 2012-09-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120232052-A1 | ARYL CARBOXAMIDE DERIVATIVES AS TTX-S BLOCKERS | SCN1B, SCN1A, SCN2B | MEN1 4046/4885KMT2A 1032/4885SPR 1986/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.